Everyone keeps talking about Merck or our BOD acti
Post# of 153815
(Total Views: 966)
Posted On: 05/19/2024 9:45:06 AM
Everyone keeps talking about Merck or our BOD acting like mob bosses and burying data, denying positive possibilities, or whatever. I think this, like most things, is a significant exaggeration of whatever the truth is. And this published trial of Keytruda plus a dud of a medication, is a great example of what we might expect in a trial with Merck. Don't get it twisted (hip phrasing for any youngsters reading), Merck wants to extend the life of Keytruda. They're clearly throwing everything at the wall in an effort to do so.
Notice they didn't create a Dud-Only arm versus a Keytruda-Only arm. A surefire way to inadvertently show that a different drug is better than your own. Keytruda is already "proven" and is going to want to run a trial that shows they can extend their patent. Similar to this trial, if we ended up in a trial with them it would, in my humble opinion, be Keytruda + LL all day. Maybe both of the doses we've had in studies (350/700).
What I don't expect is a trial that Cytodyn would run if there was no partnership, which is to compare and contrast LL to Keytruda. If Merck is running it they're just trying to show that together you see a better result, and boom! They've got new life and we've got the exciting new darling of the oncology world.
Notice they didn't create a Dud-Only arm versus a Keytruda-Only arm. A surefire way to inadvertently show that a different drug is better than your own. Keytruda is already "proven" and is going to want to run a trial that shows they can extend their patent. Similar to this trial, if we ended up in a trial with them it would, in my humble opinion, be Keytruda + LL all day. Maybe both of the doses we've had in studies (350/700).
What I don't expect is a trial that Cytodyn would run if there was no partnership, which is to compare and contrast LL to Keytruda. If Merck is running it they're just trying to show that together you see a better result, and boom! They've got new life and we've got the exciting new darling of the oncology world.
(22)
(0)